Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 30 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Triazolam Tablets. The tablets are intended for short-term treatment of insomnia and will be manufactured in Ahmedabad, India. The press release highlights that Triazolam tablets had significant annual sales in the United States according to market data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases